Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

STAT3 inhibitor

DRUG CLASS:

STAT3 inhibitor

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

No biomarker	Hepatocellular Cancer	No biomarker	Hepatocellular Cancer	TTI-101 oral Sensitive: B - Late Trials TTI-101 oral Sensitive : B	TTI-101 oral Sensitive: B - Late Trials TTI-101 oral Sensitive : B
MSI-H/dMMR	Prostate Cancer	MSI-H/dMMR	Prostate Cancer	pembrolizumab + BBI608 Sensitive: C3 – Early Trials pembrolizumab + BBI608 Sensitive : C3	pembrolizumab + BBI608 Sensitive: C3 – Early Trials pembrolizumab + BBI608 Sensitive : C3
EML4-ALK G1202R	Non Small Cell Lung Cancer	EML4-ALK G1202R	Non Small Cell Lung Cancer	ALK inhibitor + STAT3 inhibitor Sensitive: C3 – Early Trials ALK inhibitor + STAT3 inhibitor Sensitive : C3	ALK inhibitor + STAT3 inhibitor Sensitive: C3 – Early Trials ALK inhibitor + STAT3 inhibitor Sensitive : C3
BCR-ABL1 T315I	Chronic Myeloid Leukemia	BCR-ABL1 T315I	Chronic Myeloid Leukemia	NT-157 Sensitive: D – Preclinical NT-157 Sensitive : D	NT-157 Sensitive: D – Preclinical NT-157 Sensitive : D
MUC1 overexpression	Pancreatic Ductal Adenocarcinoma	MUC1 overexpression	Pancreatic Ductal Adenocarcinoma	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D
STAT3 expression	Gastric Cancer	STAT3 expression	Gastric Cancer	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D
NFKB1 expression	Gastric Cancer	NFKB1 expression	Gastric Cancer	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D	BBI608 Sensitive: D – Preclinical BBI608 Sensitive : D
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	ASP7487 + NT-157 Sensitive: D – Preclinical ASP7487 + NT-157 Sensitive : D	ASP7487 + NT-157 Sensitive: D – Preclinical ASP7487 + NT-157 Sensitive : D
PTPRD mutation	Squamous Cell Carcinoma of Head and Neck	PTPRD mutation	Squamous Cell Carcinoma of Head and Neck	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D
PTPRT promoter methylation	Squamous Cell Carcinoma of Head and Neck	PTPRT promoter methylation	Squamous Cell Carcinoma of Head and Neck	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D	JSI-124 Sensitive: D – Preclinical JSI-124 Sensitive : D
PTPRT promoter methylation	Squamous Cell Carcinoma of Head and Neck	PTPRT promoter methylation	Squamous Cell Carcinoma of Head and Neck	stattic Sensitive: D – Preclinical stattic Sensitive : D	stattic Sensitive: D – Preclinical stattic Sensitive : D
STAT3 mutation	Uterine Cancer	STAT3 mutation	Uterine Cancer	STAT3 inhibitor Sensitive: D – Preclinical STAT3 inhibitor Sensitive : D	STAT3 inhibitor Sensitive: D – Preclinical STAT3 inhibitor Sensitive : D